Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

Axovant licenses another gene therapy as new strategy beds in

Axovant licenses another gene therapy as new strategy beds in

It gives Axovant another gene therapy variant to complement OxfordBioMedica’s lentiviral-based therapy OXB-102 (no renamed AXO-Lenti-PD). ... The push into gene therapy comes after Axovant was forced to abandon its former lead candidate intepirdine for

Latest news

More from news
Approximately 97 fully matching, plus 412 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    leukaemia (ALL), Juno's share price had been in the low $20s for several months. ... Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at

  • The good, the bad and the ugly The good, the bad and the ugly

    Alzheimer’s - where 98% of drugs fail Phase III trials. ... This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinson’s house'

    Our work gives tremendous hope for Parkinson’s and also other cognitive conditions such as Alzheimer’s, if we can broaden the technology in the future.”. ... Since this article was written Pfizer has substantially scaled back its neuroscience R&D

  • Integrating digital biomarkers into precision medicine Integrating digital biomarkers into precision medicine

    Technology’s role in precision medicine is impacting the way researchers and clinicians are able to explain and predict health-related outcomes. ... burden and mild cognitive impairment in potential candidates for an Alzheimer’s study.

  • Righting pharma’s reputational wrongs Righting pharma’s reputational wrongs

    There’s something about the abbreviated name ‘pharma’ - or worse, ‘big pharma’ - that is often uttered with a sense of suspicion. ... Innovation in treatments for conditions such as cancer, Alzheimer’s and rare diseases have the potential to

More from intelligence
Approximately 1 fully matching, plus 35 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest from PMHub

  • Alzheimers disease: reviewing the immediate treatment horizon

    Alzheimer’ s disease: reviewing the immediate treatment horizon. Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to ... A recent article by BLH Consultant David Cooney

  • Alzheimer's: the numbers we cannot forget

    I would love to be talking about our latest thinking around launching new therapies in Alzheimer’ s disease (AD) but I can’ t – no one can. ... Among the worst attrition rates in the industry. 99.6% of all trials in Alzheimer’ s disease (AD)

  • Forecasting in Forgotten Markets

    This charitable fund represents collaboration between the Department of Health, Alzheimer’ s Research UK () and a number of Big Pharma companies. ... It’ s early days for this approach but there does appear to be some advantages.

  • Alzheimer's and Brain Awareness Month

    June 2017 is Alzheimer’ s and Brain Awareness Month, which aims to raise awareness about Alzheimer’ s disease (AD) and other types of dementia1. ... 5. Alzheimer's hopes dashed as Lilly gives up on amyloid drug solanezumab.

  • Atlantis Healthcare

    These include a patient’s environment, condition and motivation – along with other key behavioural drivers. ... We have delivered over 130 international support programmes across 90+ disease states including, among others: Alzheimer’s disease.

More from PMHub
Approximately 4 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics